抗CD20单克隆抗体联合CHOP化疗方案治疗人B细胞淋巴瘤的实验观察  

Experimental therapy of human B-cell lymphomas with CD20 monoclonal antibody and CHOP protocol

作　　者：高磊[1] 周倩[2] 钱卫珠[2] 范晓强[2] 郭亚军[2] 

机构地区：[1]山东省肿瘤医院外四科,山东济南250117 [2]第二军医大学肿瘤研究所,上海200433

出　　处：《中华肿瘤防治杂志》2008年第24期1864-1867,1881,共5页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:以人B细胞淋巴瘤裸鼠皮下移植模型为基础,研究抗CD20单克隆抗体体内、体外活性,评价该抗体联合CHOP化疗方案治疗人B细胞淋巴瘤的有效性。方法:体内实验:建立人B细胞淋巴瘤裸鼠皮下移植模型。52只荷瘤鼠随机分为5组进行实验。用TUNEL法检测肿瘤凋亡,并绘制肿瘤体积曲线和裸鼠体质量曲线。体外实验:用CellTiter96 AQueous非同位素细胞增殖试验试剂盒检测抗CD20单克隆抗体、化疗和联合化疗对Raji细胞体外杀伤作用,并绘制剂量反应曲线。结果:体内实验:鼠抗人CD20单抗组及嵌合CD20抗体组均出现大量肿瘤细胞凋亡。联合治疗组疗效最佳,与其他组相比差异有统计学意义,P<0.05。化疗组及联合治疗组体质量下降明显,与其他组相比差异有统计学意义,P<0.05。体外实验:发现鼠抗人CD20单克隆抗体及嵌合型CD20抗体均可增加Raji细胞对化疗药物的细胞毒敏感性。结论:CD20单克隆抗体对B细胞淋巴瘤具有明显的抑制作用,可以诱发大面积肿瘤细胞凋亡,能提高肿瘤对化疗药物的细胞毒敏感性,且较常规化疗毒副反应小。OBJECTIVE: Basing on an athymic mouse xenograft model of a CD20+ human B lymphoma cell line,to research the therapeutic efficacies of anti-CD20 mAbs in vivo and in vitro,and evaluate the therapeutic efficacies of anti-CD20 antibody,CHOP regimen and the combinatory therapy against human B lymphoma.METHODS: In vivo: Nude mice bearing human B lymphoma xenograft were established in advance.Before the therapy,52 lymphoma loaded mice were randomly divided into 5 groups.The apoptosis to tumor cells was detected by...

关 键 词：抗CD20单克隆抗体 人B细胞淋巴瘤 化学治疗 

分 类 号：R733.1[医药卫生—肿瘤]